HAWTHORNE, N.Y., Feb. 6, 2009 (GLOBE NEWSWIRE) -- Taro Pharmaceutical Industries Ltd. (“Taro,” the “Company,”) (Pink Sheets:TAROF) announced that yesterday, February 5, 2009, it received a warning letter from the U.S. Food and Drug Administration (“FDA”) regarding the inspection of the Company’s Canadian manufacturing facility in July 2008. This is the first such letter that the Company or any of its affiliates has ever received.
